Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Bicycle Therapeutics plc

Market Cap 278M 244M 225M 210M 395M 26.32B 402M 2.7B 1.04B 12.91B 1.04B 1.02B 44.88B P/E 2026 *
-1.72x
P/E 2027 * -1.9x
Enterprise Value -234M -206M -190M -177M -333M -22.18B -339M -2.28B -880M -10.88B -879M -860M -37.82B EV / Sales 2026 *
-12.8x
EV / Sales 2027 * -8.95x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day+0.50%
1 week-3.61%
Current month-14.71%
1 month-12.09%
3 months-8.05%
6 months-44.37%
Current year-43.50%
1 week 3.96
Extreme 3.96
4.24
1 month 3.95
Extreme 3.95
4.74
Current year 3.95
Extreme 3.95
7.34
1 year 3.95
Extreme 3.95
9.18
3 years 3.95
Extreme 3.95
28.67
5 years 3.95
Extreme 3.95
62.08
10 years 3.95
Extreme 3.95
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap.
04-02Sell

Chief Technology Officer

2,404 0.0063%
04-02Sell

Chief Financial Officer

901 0.0024%
04-02Sell

Chief Operating Officer

1,408 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%-3.61%-46.09%-85.15% 278M
+2.14%+6.81%+72.57%+123.91% 56.65B
-0.49%+6.98%+62.88%+67.95% 47.49B
+0.48%-0.20%-14.93%-15.55% 22.81B
+3.60%+4.81%-0.52%+402.21% 21.37B
+1.30%+0.71%+29.21%-17.51% 16.12B
+3.20%+7.18%+24.07%-34.39% 15.56B
-0.02%-3.13%+27.17%+158.25% 12.91B
0.00%+15.02%+133.24%+273.89% 12.86B
+1.43%-5.06%+23.53% - 11.67B
Average +1.21%+1.16%+31.11%+97.07% 21.77B
Weighted average by Cap. +1.25%+3.16%+45.55%+112.65%

Financials

2026 *2027 *
Net sales 18.24M 16.02M 14.76M 13.82M 25.91M 1.73B 26.37M 178M 68.52M 847M 68.45M 66.97M 2.95B 14.11M 12.4M 11.42M 10.69M 20.05M 1.34B 20.41M 137M 53.03M 656M 52.98M 51.83M 2.28B
Net income -154M -135M -124M -116M -218M -14.55B -222M -1.5B -577M -7.14B -577M -564M -24.82B -162M -143M -131M -123M -231M -15.38B -235M -1.58B -610M -7.54B -609M -596M -26.22B
Net Debt -512M -450M -414M -388M -728M -48.5B -741M -4.98B -1.92B -23.78B -1.92B -1.88B -82.71B -404M -355M -327M -306M -574M -38.28B -585M -3.93B -1.52B -18.77B -1.52B -1.48B -65.29B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
23/06/26 $4.000 +0.50% 405,566
22/06/26 $3.980 -0.50% 607,836
18/06/26 $4.000 -0.99% 317,931
17/06/26 $4.040 +0.50% 969,140
16/06/26 $4.020 -3.13% 947,788
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.000USD
Average target price
12.62USD
Spread / Average Target
+215.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!